Investor FAQs

Cartherics was formed in 2015 and began work in 2016. By 2022 there were 45 members of staff and principal consultants and the company opened new state of the art PC2 and clean room laboratories close to Monash University. The company is establishing clinical scale product manufacturing and plans to enter clinical trials in 2023 […]

Cartherics approach is to utilise the power of pluripotent stem cells, which are immortal and may be gene edited, to produce a continuous stream of products with therapeutic potential as “off-the-shelf” availability for patients with intractable cancers. The potential to mix and match CAR targets, immune cell types (T cells, NK cells, macrophages, etc.) with […]

Cartherics has a strong research team experienced in immunology, stem cell and cancer biology, product development, animal cancer models, patenting, product development and commercialisation. The research team generates the new ideas and brings these to proof of principle, the translation team generates the preclinical data, and the development team develops the products for clinical trial. […]

Cartherics has developed a platform technology that underpins production of immune therapies based on different killer cell types, multiple CARs targeting cancer antigens, and suppression of immune inhibitory genes that can prevent the cells ability to attack tumours. The products evolving from the pipeline will be developed through clinical trials and partnered for development and […]

Cell biology; cell culture and expansion; gene editing using lentiviral vectors or CRISPR/Cas9; assessment of genomic stability of stem cells and their differentiation products; animal models for cancer; immune cell biology and function assays; differentiation of pluripotent stem cells into T cells, Natural Killer (NK) cells, macrophages and other immune cell types; Immune cell killing […]